Skip to content

Cogent Biosciences

US · COGT #2052 by market cap Listed 2016
26.72 -1.03 -3.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:53

About Cogent Biosciences

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Founded
2014
CEO
Mr. Andrews R. Robbins, M.B.A.
Employees
258
Headquarters
Waltham, Massachusetts, United States of America
Fiscal year end
12-31
Website
cogentbio.com

Company profile

Exchange
US
Symbol
COGT
Market-cap rank
#2052
Listing date
2016-09-26
Market cap
4.65B
Float cap
4.62B
Shares out
173.99M
Float shares
172.99M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:53:23 · For reference only, not investment advice and not tailored to your situation.

Cogent Biosciences discussion 0 comments

Add a comment